EUCTR2012-005222-30-IT进行中（未招募）1 期
Feasibility study to assess safety of high dose of lanreotide in net patients poorly controlled by standard doses of SSA - Lanreotide at high dosages in NET
IVERSITA' DI GENOVA0 个研究点开始时间: 2013年1月11日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Subjects of both gender, aged =18 years AND = 75 years 2) patients with histological diagnosis of WD NETs, defined according to the recent WHO classification for gastroentero pancreatic (WHO 2010), bronchial and thymic NET(WHO 2004) or with hepatic metastases documented through a bioptic exam and Occult Primary tumor; patient with or without carcinoid syndrome could be enrolled; 3) Patients on treatment with standard dosages of octreotide LAR (30 mg/28 days) or lanreotide Autogel (120 mg/28 days) in the 6 months before enrollment; 4) Patients with tumor/biochemical/ symptomatic disease progression 5) Urine negative pregnancy test for women of childbearing age. Female subjects of childbearing potential must be using an appropriate method of contraception like double-barrier contraception , oral estroprogestinic contraceptive or an intrauterine device (IUD). Patient must be willing to continue using it throughout the entire study period, until two month after the study end; if the patient is a man, if the partner is a childbearing potential female, he should agree to using appropriate method of contraception;
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. patients initially not responsive to SSA 2. patient naive to any treatment to SSA analogues 3. stable disease on treatment with SSA at standard dosages; 4. previous surgical treatment for NET in the 4 weeks before enrollment or planned during the study; 5. symptomatic colelitiasis 6. unstable angina, supported ventricular tachycardia, ventricular fibrillation, myocardial infarction in three months before enrollment; 7. hepatic disease here included cirrhosis, chronic or active hepatitis, permanent increase of AST, ALT, alkaline phosphatase 2xULN (upper limit normal) or increase of AST, ALT, alkaline phosphatase 4xULN (upper limit normal) in patients with hepatic metastases, total bilirubin 1.5xULN or creatinine 1.5xULN; 8. Specific previous antitumor treatment, here included, chemotherapy, chemoembolization, radiotherapy, PRRT or interferon in the 6 months before enrollment or planned during the study (based in investigator judgment) 9. Previous neoplastic disease (excepted basal cell carcinoma, cervical carcinoma in situ or uterine cancer, thyroid microcarcinoma or thyroid and prostate carcinoma surgically eradicated). Patients with carcinoma diagnosis can be enrolled in the study only if treated with a curative intent and free from disease from at least 5 years; 10. Decompensated diabetes mellitus (HbA1c> 8%); 11. Pregnant or breast-feeding women; Female subjects of childbearing potential not using an appropriate anticonceptive method 12. Hypersensitivity to lanreotide 13. Presence of adverse events (grade>1 according to NCI CTCAE (Versione 3.0) criteria) related to SSA treatment at inclusion
研究者
相似试验
已完成
不适用
Investigation for efficacy and safety of high dose chemotherapy (MEAM) supported with auto-PBSCT for malignant lymphoma (THF 13)Malignant lymphomaJPRN-UMIN000002743TOHOKU HEMATOLOGY FORUM30
已完成
不适用
Safety evaluation studies of high dose intake of capsules including herb extractHealthy adultJPRN-UMIN000028987TTC Co., Ltd.10
已完成
不适用
Safety evaluation studies of high dose intake of a food aiming for official recognition as a Food with Function Claims.Healthy volunteersJPRN-UMIN000035164Kochi University12
已完成
2 期
Anti aging efficacy of HIFU therapy using Anika deviceIRCT20190210042676N5Parnian Gostar Parto Sanj company30
已完成
不适用
Safety evaluation studies of high-dose ingestion of mangosteen soft capsuleJPRN-UMIN000023284TTC Co., Ltd.10